Received Apr 15, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 34HG2 | — |
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
Havrix pediatric dose administered to an adult patient; Havrix pediatric dose administered to an adult patient; first dose of adult Havrix was administered on 9/27/2006; first dose of adult Havrix was administered on 9/27/2006; This non-serious case was reported by a other health professional via call center representative and described the occurrence of underdose in a 11-year-old female patient who received HAV (Havrix pediatric) (batch number 34HG2, expiry date 12-AUG-2027) for prophylaxis. Co-suspect products included HAV (Havrix adult) for prophylaxis. On 07-APR-2026, the patient received the 2nd dose of Havrix pediatric. On 27-APR-2006, the patient received the 1st dose of Havrix adult. On 27-APR-2006, an unknown time after receiving Havrix adult, the patient experienced overdose (Verbatim: first dose of adult Havrix was administered on 9/27/2006) and adult product administered to child (Verbatim: first dose of adult Havrix was administered on 9/27/2006). On 07-APR-2026, the patient experienced underdose (Verbatim: Havrix pediatric dose administered to an adult patient) and adult use of a child product (Verbatim: Havrix pediatric dose administered to an adult patient). The outcome of the underdose, adult use of a child product, overdose and adult product administered to child were not applicable. Additional Information: GSK receipt date: 07-APR-2026 The batch number was not provided upon follow-up with the reporter.